Current and Future Therapies for β-Thalassaemia: A Review Article

Abstract

This article will review recent and forthcoming advances in the treatment of thalassaemia. Prognosis of thalassaemia has dramatically improved in the last 50 years with the development of regular and safe blood transfusions and iron chelation. Almost 20 years ago, development of oral chelators, and more recently the improvement in the knowledge and understanding of iron pathophysiology, have led to optimal iron toxicity prevention and treatment. These considerable advancements in medical therapy have transformed transfusion-dependent thalassaemia from a lethal childhood disease to a chronic disease with an open prognosis, even in those individuals over 50 years of age, and with the disease being, in some instances, curable. In the 1980s, the introduction of allogeneic haematopoietic cell transplantation provided the possibility of curing the congenital disease for the first time. More recent developments include an improved understanding of erythropoiesis, which led to the development of new erythroid-stimulating factors effective in thalassaemia, an expansion of donor pull for transplantation, and the approach of the long-term promised gene therapy in clinical practice. Moreover, ongoing trials of gene editing and agents modulating iron metabolism promise new improvements. Today, patients with thalassaemia have several weapons in their therapeutic arsenal and, hopefully, will have much more to come. As usual in medical practice, new advancements provide new challenges for the medical community, and it is the duty of this community to clearly understand the benefits and challenges of any new approach in order to provide the highest clinical benefit to patients.

INTRODUCTION

β-thalassaemias are a clinically heterogenous group of inherited disorders caused by >200 described mutations in the β-globin gene, leading to a decreased or absent production of the β-globin chain. The hallmark of the disease is the imbalance in the α/β-globin chain production, which results in variable grades of ineffective erythropoiesis for apoptosis of late-stage erythroid precursors, chronic haemolytic anaemia, compensatory haemopoietic expansion, hypercoagulability, and increased iron absorption.1 Approximately 1.5% of the global population are carriers for a β-thalassaemia mutation, with traditionally higher prevalence in populations where malaria
is or was endemic such as the Middle East, the Mediterranean region, and Southeast Asia; however, prevention programmes and migrations have recently contributed to a change in the pattern of thalassaemia distribution worldwide. Improved public health measures have prolonged life expectancy of affected individuals in low- and middle-income countries, making β-thalassaemia a significant global health problem.

Current guidelines have adopted a clinical classification of thalassaemia syndromes based on the magnitude and frequency of transfusion requirements, which are considered to reflect the severity of the disease. Patients with transfusion-dependent thalassaemia (TDT) present with severe anaemia as early as 6 months of age and require life-long blood transfusion to survive. Conversely, in non-transfusion-dependent thalassaemia (NTDT), patients usually maintain haemoglobin (Hb) levels between 7 and 10 g/dL and may require transfusions sporadically. They eventually develop clinically significant iron overload, mainly as a consequence of erythron expansion and increased duodenal iron absorption driven by hepcidin suppression.

This review aims to provide a summary of the current and emerging treatment strategies for β-thalassaemia.

CURRENT TREATMENTS (STANDARD THERAPY)

Transfusion and Chelation

The aim of red blood cell transfusion in thalassaemia is to restore normal Hb values and to suppress ineffective erythropoiesis, thus attenuating the downstream consequences. In chronically transfused patients with TDT, the transfusion-mediated rise in Hb suppresses erythropoiesis and is associated with a rise in hepcidin levels. Improvements in blood product administration practices and more effective iron chelation were associated with better survival outcomes and fewer cardiac complications. The best course of action to suppress abnormal erythropoiesis, minimise iron overload, guarantee normal growth, and avoid hyperviscosity contemplates a pre-transfusion level between 9 and 10.5 g/dL, with a higher target of 11–12 g/dL for patients with cardiac involvement or with extramedullary pseudotumours. Conversely, in NTDT, transfusion may be indicated sporadically or for temporary periods in specific situations; clear evidence regarding the most appropriate target of pre-transfusion Hb in NTDT is lacking and some patients, specifically those with the HbE/β-thalassaemia genotype, seem to be able to adapt to lower Hb levels. Patients with NTDT placed on transfusion regimens seem to have fewer complications deriving from chronic anaemia and ineffective erythropoiesis (extramedullary haematopoiesis, pulmonary hypertension, thrombotic events); on the other hand, given the increased risk of alloimmunisation and particularly of secondary iron overload under chronic transfusion regimens, the decision to commit to a regular transfusion programme must be well thought-out and patients must be evaluated a long time before/after acute episodes.

In TDT, transfusion iron can accumulate at a rate of 0.3–0.6 mg/kg with a standard chronic transfusion regimen; iron from senescent red blood cells is stored mainly by reticuloendothelial macrophages and rapidly released into the plasma, where transferrin is saturated and labile toxic iron species emerge. The most important advancement in iron chelation treatment has been the understanding that iron tissue toxicity is not only related to iron overload but to the presence of toxic iron species in the plasma. Therefore, iron chelation therapy (ICT) is administered with the primary goal of removing iron oxidative species emerging in the plasma after transferrin saturation, and the secondary goal of removing formerly deposited iron. An iron overload assessment is thus recommended as soon as 10 units of red blood cells have been transfused, through liver iron concentration (LIC) measurement by MRI or, if not applicable or unavailable due to limited resources, through serum ferritin level measurement. For TDT, a threshold of >1,000 ng/mL is usually an indication for ICT requirement and a value >2,500 ng/mL strongly correlates with cardiac siderosis and endocrinopathy.

In NTDT, iron overload is related to increased intestinal absorption secondary to suppressed hepcidin. Hepcidin is synthesised in the liver and promotes degradation of ferroportin, the only known cellular iron exporter expressed on
macrophages, hepatocytes, and on the basolateral membrane of enterocytes, thus reducing iron absorption. Ineffective erythropoiesis and erythroid expansion have been suggested to promote suppression of hepcidin, despite the onset of iron overload, through production of the erythroblast-derived factor erythroferrone. This results in a slower rate of iron accumulation in NTDT compared to TDT and in a different distribution, with slower or absent myocardial involvement even in the presence of elevated LIC. Guidelines recommend ICT if LIC is >5 mg iron/g dry weight or serum ferritin is >800 ng/mL, although more recent data showed significant iron overload for ferritin values in the 300–800 ng/mL range.

Three iron chelators are licensed by most regulatory agencies for thalassaemia (deferoxamine [DFO], deferasirox, and deferasirox monotherapy at a dose of 20–40 mg/kg once daily proved effective as a first-line therapy for transfusional iron overload in TDT for reducing serum ferritin and LIC and ameliorating myocardial T2* on MRI, even in heavily iron-overloaded patients. Deferasirox is also the only iron chelator evaluated in a randomised clinical trial in NTDT, showing efficacy in reducing LIC in patients ≥10 years of age with a baseline value of at least 5 mg iron/kg dry weight. Deferiprone is an oral (administration 3 times per day) absorbed iron chelator licensed in most countries as a second-line therapy for iron overload in patients with TDT >6 years of age. Its efficacy in LIC reduction has also largely been demonstrated. Sporadic severe cases of granulocytopenia have been reported. Notably, a combination therapy of DFO and deferasirox proved effective in the management of cardiac overload, by ameliorating cardiac T2* on MRI and left ventricular ejection fraction. Allogeneic Haemopoietic Cell Transplantation

The rationale for haematopoietic cell transplantation (HCT) in thalassaemia is to replace ineffective endogenous erythropoiesis and to correct the phenotypic expression of the disease, sparing patients from life-long transfusion treatment and long-term complications. HCT is, so far, the only consolidated approach with a curative potential in TDT. Transplantation in TDT is now performed worldwide with excellent results. The latest report from The European Society for Blood and Marrow Transplantation (EBMT) Registry showed a global overall survival (OS) and event-free survival (EFS) of 88% and 81%, respectively, with best results obtained in patients ≤14 years of age (OS and EFS of 90% and 83%, respectively). Current recommendations identify young patients with TDT, before development of iron-related organ damage, as the ideal candidates for HCT; adults can also be offered this strategy in the setting of dedicated programmes, provided that they have been well-chelated since infancy. According to the EBMT Registry data, better outcomes are still obtained from transplants with human leukocyte antigen (HLA)-matched siblings, with an OS of 91% and EFS of 83%.

The possibility of finding an HLA-matched sibling donor ranges from 60 to 70% in countries where families are larger and an average of 25–30% in western countries, highlighting the need for alternatives. In the era of high-resolution HLA typing, transplantation from matched unrelated donors in TDT is considered feasible and effective. Transplantation from alternative donors has resulted in conflicting results so far. Primary graft failure appears as the major complication of unrelated cord blood unit transplants, while the need to abate the risk of graft-versus-host disease has prompted the search for effective modalities of ex vivo or in vivo T-cell depletion with grafts from haploidentical donors. Recent reports of alternative HCT donors are summarised in Table 1.
### Table 1: Haematopoietic stem cell transplantation from alternative donors in patients with thalassaemia.

| Study; number of patients | Donor | Manipulation | Conditioning | GVHD prophylaxis | Results (OS, TFS, GF) | Notes |
|---------------------------|-------|--------------|--------------|------------------|-----------------------|-------|
| Li et al., 2019; 355      | MUD/MMUD | none         | MAC Bu based | Various          | OS: 87% MUD, 78% MMUD; TFS: 82% MUD, 78% MMUD; GF: 6% MUD, 11% MMUD | aGVHD 21%; cGVHD 13% |
| Fleischauer et al., 2006; 72 | MUD/MMUD | none         | Bu Cy, Bu Cy TT, Bu Flu TT | CsA+MTX, ATG+CsA+MTX (25%) | OS: NR; TFS: 76% HLA DPB1 matched or permissive, 57% HLA DPB1 non-permissive; GF: 10% | aGVHD 27% |
| Huang et al., 2018; 50    | MUD/MMUD | none         | Bu Cy Flu    | ATG+CsA+MTX      | OS: 94%; TFS: 92%; GF: 0% | Median age: 4.6 years (range: 2–12 years) |
| Ruggeri et al., 2011; 35/51 | Unrelated UCB | none         | MAC 30/35    | CsA-based 27/35  | OS: 65%; TFS: 21%; GF: 52% | none |
| Jaing et al., 2012; 35    | Unrelated UCB | none         | Bu-Cy        | ATG+CsA+MP       | OS: 88%; TFS: 74%; GF: 12% | none |
| Gaziev et al., 2018; 40   | Haploidentical | CD3+/CD19+ depletion | Bu-TT-Cy (preceded by Flu) | ATG+CsA+MP    | OS: 78%; TFS: 39%; GF: 45% | none |
| Gaziev et al., 2018; 11/14 | Haploidentical | qβ/CD19+ depletion | Bu-TT-Cy (preceded by HuAzFlu) | ATG + CsA+MP/MMF | OS: 84%; TFS: 69%; GF: 14% | none |
| Anurathapan et al., 2020; 83 | Haploidentical | none         | ATG-Bu-Flu (preceded by DxmFluVelRit) | PT-Cy +tacrolimus/sirolimus | OS: 96%; TFS: 96%; GF: NR | 52 patients treated with the full pretransplant immunosuppression protocol engrafted uneventfully |

aGVHD: Acute graft-versus-host disease; ATG: anti-thymocyte globulin; Az: azathioprine; Bu: busulfan; cGVHD: chronic graft-versus-host disease; CsA: cyclosporin A; Cy: cyclophosphamide; Dxm: dexamethasone; Flu: fludarabine; GF: graft failure; GVHD: graft-versus-host disease; HLA: human leukocyte antigen; Hu: hydroxyurea; MAC: myeloablative conditioning; MMF: mycophenolate mofetil; MMUD: mismatched unrelated donor; MP: methylprednisolone; MTX: methotrexate; MUD: matched unrelated donor; N/A: not applicable; NR: not reported; OS: overall survival; PT-Cy: post-transplant cyclophosphamide; Rit: rituximab; TFS: thalassaemia-free survival; TT: thiopeta; UCB: umbilical cord blood; Vel: velcade.
Erythroid Maturating Agents

Members of the TGF-β superfamily of ligands, including several bone morphogenetic proteins, growth-differentiation factors, and activins, have been known to be inhibitors of late-stage erythropoiesis. Their complex interaction with erythroid precursors was recently reviewed. Actin receptor ligand traps (sotacert and luspatercept) are fusion proteins that act as extracellular traps for a wide range of ligands of the TGF-β superfamily, thereby preventing receptor binding and stimulation of downstream signalling. This approach proved capable of correcting anaemia in an erythropoietin (EPO)-independent fashion in mouse models of ineffective erythropoiesis, thus raising interest surrounding its possible clinical application in thalassaemia or myelodysplastic syndromes. The specific pathway inhibited by these drugs is still a matter of debate, with growth-differentiation factor-11 signalling primarily hypothesised as the major target; however, this was recently contradicted by further experiments on murine models.

Luspatercept (ACE-536) is an activin Type IIa ligand trap, binding to several members of the TGF-β superfamily. It has recently been approved by the U.S. Food and Drug Administration (FDA) and by the European Medicines Agency (EMA) for the treatment of anaemia in TDT and EPO-refractory myelodysplastic syndrome with ring sideroblasts. Results from a Phase II trial led to the initiation of the randomised, Phase III BELIEVE clinical trial of luspatercept in 336 adult patients with TDT in 15 countries. The percentage of patients who had a minimum reduction of 33% of transfusion burden was higher in the luspatercept arm than the placebo arm for fixed predefined time periods (from baseline to Weeks 13–24: 21.4% versus 4.5%; from baseline to Weeks 37–48: 19.6% versus 3.6%, respectively) and during any 12-week period (70.5% versus 29.5%, respectively). Subgroup analysis revealed that the magnitude and rapidity of response might be lower in patients with a β0/β0 genotype than in patients with a non-β0/β0 genotype. Adverse events were mainly Grade 1 and 2 and consisted of bone, back, and musculoskeletal pain, headache, myalgia, arthralgia, and injection site pain. However, in this randomised trial, eight thromboembolic events (deep vein thrombosis, ischaemic stroke, superficial thrombophlebitis, pulmonary embolism) were reported, all in patients who had previously undergone splenectomy.

Given the central role of the JAK2/STAT5-signalling pathway in EPO/EPO receptor interaction on erythroblasts, JAK2 inhibition was tested as a potential mechanism for reversing ineffective erythropoiesis. Despite initial promising results, when ruxolitinib was tested in a Phase IIa study for patients with TDT with splenic enlargement, no significant Hb increase from baseline was observed nor significant changes in total body iron concentration.

Gene Therapy: Gene Insertion Approaches

While HCT has long been considered the only curative treatment for thalassaemias, its applicability is hampered by the availability of a full-matched, HLA-identical donor, by the risk of immunological complications, and by the need for long-term immunosuppression. The goal of current gene therapy is to provide a curative option for patients lacking HLA-identical siblings by inducing the production of the β-globin or γ-globin, thus improving the α/non-α globin ratio, decreasing the deposition of insoluble α-hemichromes, and correcting ineffective erythropoiesis. This can be achieved through two different major platforms: gene insertion and gene editing.

The first approved gene therapy product approved in Europe for the treatment of patients with TDT aged ≥12 years with a non-β0/β0 genotype, candidates for HCT but lacking an HLA-identical sibling, is LentiGlobin BB305 approved in 2019, and belongs to the first category; this consists of inserting a lentiviral vector containing the β-globin-producing genes together with their regulatory machinery (promoter, enhancer, and part of the locus control region) into previously collected autologous haematopoietic peripheral blood stem cells (PBSC) and later infusing these genetically modified PBSCs back into the patient after proper myeloablation to facilitate engraftment. The β-globin-producing sequences are placed under the control of an erythroid promoter, so that they can only be transcribed in erythroid precursors. However, this process remains fairly
uncontrolled and, despite the optimisation of the more recent lentiviral vectors, occurs ‘semi-randomly’, potentially retaining a risk of clonal proliferation stimulation. For this reason, the FDA and EMA require a total follow-up of 15 years for all patients treated with gene therapies.

LentiGlobin BB305 was tested in two Phase I/II trials on a total of 22 patients aged 12–35 years with TDT of any genotype. The conditioning regimen consisted of myeloablative doses of busulfan modulated by pharmacokinetic (PK) analysis. All patients attained engraftment and 10% developed veno-occlusive disease and required defibrotide treatment. The vector copy number of infused products ranged from 0.3 to 1.5 in the first trial and from 0.8 to 2.1 in the second trial. The gene-insertion-derived HbA, separately identified by liquid chromatography due to an amino-acid substitution (HbA\(^{T87Q}\)), was produced at an average of 6 g/dL in non-\(\beta^0\beta^0\) genotypes, granting transfusion independence in all but one patient. Subsequent efforts have focused on improving the transduction process, elevating the vector copy number of the final product to a median of three copies per double-stranded DNA. The results of the Phase III Northstar-2 and Northstar-3 trials show a stable Hb ≥ 11 g/dL in 91% of patients with non-\(\beta^0\beta^0\) genotype, and 3 out of 4 \(\beta^0\beta^0\) patients followed-up for ≥ 6 months having stopped transfusions. The commercialisation of LentiGlobin for TDT has recently been suspended after two myeloid neoplasms were diagnosed in patients with treated sickle cell disease during follow-up. These events will need to be clarified before proceeding with a large clinical application.

In Italy, nine patients were treated with the GLOBE lentiviral vector-transduced autologous haematopoietic PBSCs, with intra-bone administration to avoid trapping into filter organs and allow for better and earlier haematopoietic recovery. The most significant gene therapy clinical trials conducted so far in TDT are listed in Table 2.

Although gene therapy overcomes the risk of graft-versus-host disease and the need for a suitable donor, there are several challenges still to be faced. 1) Busulfan-based myeloablative conditioning is not devoid of toxicity and some attempts have been made to minimise it, such as dose-tailoring based on PK or the use of the less-toxic thiopeta and treosulfan. 2) Long-term follow up is still not available and the number of treated patients so far is not enough to have a complete safety profile. 3) A large number (≥10–15x10^6 CD34+/kg) of stem cells is required to account for stem cell losses during manufacturing, demanding for upfront plerixafor. 4) Unlike stem cell transplantation, where the \(\beta\)-globin defect correction occurs in a pan-cellular fashion (e.g., in every donor-derived stem cell), the number of gene insertions in PBSC can vary depending on the efficiency of manufacturing processes, leading to a heterocellular correction and strongly demanding for an adequate characterisation of the product prior to infusion, at least in terms of viability, purity, and efficiency of the transduction process. 5) In order to be potentially manufactured on a large scale, costs and quality of life should be superimposable compared to alternative-donor HCT, and a socioeconomic advantage over the costs of life-long transfusions and chelation should be demonstrated.

**FUTURE TREATMENTS**

**Gene Therapy: Gene Editing Approaches**

The gene editing approach exploits the possibility to precisely cut human DNA at specific locations by engineered nucleases, such as zinc-finger nucleases and CRISPR/Cas9. By doing so, they can either act on specific erythroid enhancer regions regulating the switch from the \(\gamma\)-globin genes to the \(\beta\)-globin genes, or recreate the mutations seen in hereditary persistence of fetal Hb, thus incrementing the production of fetal Hb. This method retains the advantage of a higher precision and efficiency in DNA edits and of more affordable costs.

Recently, the results of the first patient treated with a CRISPR/Cas9 gene-editing product, targeting the enhancer of the \(BCL11A\) gene on chromosome 2, were presented (CTX001 product): the patient (\(\beta^0/IVS-1-110\) genotype) was transfusion-independent at 12-months follow-up and 99% of erythrocytes expressed high levels of fetal Hb.
More attempts are ongoing with CRISPR/Cas12 products performing edits on the \textit{BCL11A} binding site on the \textit{HBB} gene; this process demands extreme precision in order to prevent disruption of endogenous globin production. The main limitation lies in the risk to create unintended edits in the genome (‘off-target effects’), although this is not necessarily of clinical significance; additionally, chromosomal rearrangements or instability can occur and require serial monitoring.

**Iron Metabolism Modifying Agents (Minihepcidines, Ferroportin Inhibitors)**

The hepcidin/ferroportin axis is a major regulator of erythropoiesis; ineffective erythropoiesis with low or inappropriately normal hepcidin levels and subsequent iron overload are hallmarks of the so-called ‘iron-loading anaemias’, with NTDT as a prototype, thus the possibility to therapeutically target this axis has recently gained some interest.

---

**Table 2: Gene insertion approaches in clinical trials.**

| Study; Sponsor | Vector | Number of patients | Genotype | Conditioning | Graft source; administration route | Results |
|----------------|--------|--------------------|----------|--------------|-----------------------------------|---------|
| HGB-204 and HGB-205, Thompson et al., 2018; Bluebird | BB305 T87Q encoding human β-globin LV vector (former HVP569) with removal of insulators | 22 | TDT all genotypes | PK-guided busulfan | mPBS; intravenous | 12/13 non-β0β0 patients became TI 3/9 β0β0 patients became TI |
| HGB-207 Northstar-2, Thompson et al., 2019; Bluebird | As above | 20 | TDT non-β0β0 genotype | PK-guided busulfan | mPBS; intravenous | 4/5 evaluable patients became TI |
| HGB-212 Northstar-3, Lal et al., 2019; Bluebird | As above | 11 | TDT either β0 or β0 IVS-I-110 mutations on both \textit{HBB} alleles | PK-guided busulfan | mPBS; intravenous | 3/4 evaluable patients became TI |
| TIGET-BTHAL, Marktel et al., 2019; Telethon Foundation | GLOBE lentiviral vector | 9 | TDT either β0β0 or severe β+ genotypes | RTC treosulfan + thiotepa | mPBS; intrabone | 3 adults reduced transfusion requirements 3/4 evaluable children became TI |
| NCT 01639690, Maggio et al., 2020; Memorial Sloan Kettering | TNS9.3.S5.A1 Target=10 | β-thalassaemia major, transfusion dependent | Busulfan 8–14 mg/kg | mPBS; intravenous | Estimated completion date: July 2021; 2/3 evaluable patients reduced transfusion requirements |

mPBS: Mobilised peripheral blood stem cells; PK: pharmacokinetics; RTC: reduced toxicity conditioning; TI: transfusion independent; TDT: transfusion-dependent thalassaemia.
Studies on β-thalassaemia in mouse models demonstrated that transgenic overexpression of hepcidin or genetic disruption of hepcidin regulators can result in the prevention of iron overload and enhance haemopoiesis. Biosynthesis of full-length hepcidins is inefficient and they are rapidly cleared by the kidneys; however, these limitations were somehow overcome by the development of minihepcidins (MH): short, engineered peptides with an increased half-life and potency, able to mimic the iron-restrictive effect of endogenous hepcidin. In young Hbb\textsuperscript{th3/+} mice, serving as models for NTDT, MH ameliorated anaemia, ineffective erythropoiesis, splenomegaly, and iron overload. In older mice, the administration of MH together with deferiprone did not modify its beneficial effect on iron overload. In TDT mice models, MH in combination with chronic red blood cell transfusions further improved ineffective erythropoiesis, splenomegaly, and iron overload. Based on these results, multiple trials were started to assess efficacy of MH in the clinical setting. In a Phase II study, LJPC-401 was tested for the treatment of myocardial iron overload in patients with TDT but the trial was prematurely terminated because of absence of efficacy.

Another approach to modulate iron metabolism is through ferroportin inhibitors. Among these, VIT-2763 is a small, oral compound that competes with hepcidin for ferroportin binding. In the Hbb\textsuperscript{th3/4} mice, it ameliorated ineffective erythropoiesis and the dysregulated iron homeostasis; it also corrected the proportion of myeloid precursors in Hbb\textsuperscript{th3/4} mice spleens.

A Phase I, double-blind, dose-escalating study was performed in order to assess for safety, tolerability, PK, and pharmacodynamic properties of VIT-2763 in healthy volunteers: no serious events led to drug discontinuation and most of the adverse events in the single and multiple escalating dose cohorts were drug-unrelated; a temporary decrease in mean serum iron and mean transferrin saturation were observed. A Phase II, randomised, double-blind trial assessing efficacy, safety, and tolerability of VIT-2763 is currently recruiting in multiple sites.

**CONCLUSION**

The last 50 years have witnessed dramatic improvements in thalassaemia understanding and patient care. These improvements have built a series of previously unimaginable therapeutic opportunities for patients with thalassaemia, with many more on the way. All of this was made possible by a synergy between the various fields of biological and clinical research, which have mutually reinforced one another to lead to shared success. Figure 1 reports the milestones of therapeutic progress in β-thalassaemia.

Having access to many therapeutic opportunities is undoubtedly beneficial for patients, yet it can also lead to problems when choosing treatment. As opportunities have grown, the cost of optimal therapies has increased dramatically, and so has the demand for a better selection of the appropriate sequence of treatments in terms of cost/benefit ratio. When compared to HCT (the only other available curative option), gene therapy results

---

**Figure 1: Milestones of therapeutic advances in β-thalassaemia, revealing continuous improvement during recent decades.**

| 1970 | 1980 | 1990 | 2000 | 2010 | 2020 | next |
|------|------|------|------|------|------|------|
| Safe and regular blood transfusions; iron chelation | Haemopoietic cell transplantation | Improving transplantation and iron chelation | Oral chelators | Improving iron metabolism knowledge; gene therapy | New erythroid-stimulating agent | Gene editing; iron metabolism modulating agents |
income countries. Traditional treatments, on the other hand, are not devoid of costs, estimated around 30,000 EUR/year/patient for TDT in Italy, making HCT at younger ages, when feasible, probably the most appropriate choice in the circumstance, even in terms of resource application. In conclusion, in order for the points discussed in this article to become common practice, an effort must be made to progress, consistent with resource availability and still crucially impacting the real opportunities for benefiting from these advances in the real world.
30. Angelucci E et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica. 2014;99(5):811-20.

31. Jawdat DM et al. Chances of finding an HLA-matched sibling: the Saudi experience. Biol Blood Marrow Transplant. 2009;15(10):1342-4.

32. Li C et al. Related and unrelated donor transplantation for b-thalassemia major: results of an international survey. Blood Adv. 2019;3(17):2562-70.

33. Fleischauer K et al. Graft rejection after unrelated donor hematopoietic stem cell transplantation for thalassemia is associated with nonpermissive HLA-DPBI disparity in host-versus-graft direction. Blood. 2006;107(7):2984-92.

34. Huang K et al. Modified conditioning regimen improves outcomes of unrelated donor peripheral blood stem cell transplantation for b-thalassemia major patients. Pediatr Blood Cancer. 2018;65(7):e27026.

35. Ruggeri A et al. Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. Biol Blood Marrow Transplant. 2011;17(9):1375-82.

36. Jaing TH et al. Unrelated cord blood transplantation for thalassemia: a single-institution experience of 35 patients. Bone Marrow Transplant. 2012;47(1):33-9.

37. Gaviz J et al. Haploidentical HSCT for hemoglobinopathies: improved outcomes with TCRαβ+/CD19+-depleted grafts. Blood Adv. 2018;2(5):263-70.

38. Anurathapan U et al. Hematopoietic stem cell transplantation for severe thalassemia patients from haploidentical donors using a novel conditioning regimen. Biol Blood Marrow Transplant. 2020;26(6):1106-12.

39. Pilo F, Angelucci E. Luspatercept to treat beta-thalassemia. Drugs Today. 2020;56(7):447-58.

40. Suragani RNVS et al. Modified activin receptor IIb ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia. Blood. 2014;123(25):3864-72.

41. Guerra A et al. Lack of Gdf11 does not improve anemia or prevent the activity of RAP-536 in a mouse model of β-thalassemia. Blood. 2019;134(6):568-72.

42. Markham A. Luspatercept: first approval. Drugs. 2020;80(1):85-90.

43. Piga A et al. Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with 8-thalassemia. Blood. 2019;133(12):1279-89.

44. Cappellini MD et al. A phase 3 Trial of luspatercept in patients with transfusion-dependent 8-Thalassemia. N Engl J Med. 2020;382:1219-31.

45. Breda L, Rivella S. Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production. Hematol Oncol Clin North Am. 2014;28(2):375-86.

46. Casu C et al. Short-term administration of JAK2 inhibitors reduces splenomegaly in mouse models of β-thalassemia intermedia and major. Haematologica. 2018;103(2):e46-9.

47. Taher AT et al. Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study. Blood. 2018;131(2):263-5.

48. Soni S. Gene therapies for transfusion dependent β-thalassemia: current status and critical criteria for success. Am J Hematol. 2020;95(9):1099-112.

49. Schuessler-Lenz M et al. Regulators’ advice can make a difference: European Medicines Agency approval of zynteglo for beta thalassemia. Clinical Pharmacology & Therapeutics. 2019;107(3):492-4.

50. Payen E et al. Lentivirus vectors in β-thalassemia. Methods Enzymol. 2012;507:109-24.

51. Moiani A et al. Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts. J Clin Invest. 2012;122(5):1653-66.

52. Thompson AA et al. Gene therapy in patients with transfusion-dependent β-Thalassemia. N Engl J Med. 2018;378(16):1479-93.

53. Thompson AA et al. Northstar-2: updated safety and efficacy analysis of lentiglobin gene therapy in patients with transfusion-dependent β-thalassemia and non-β0/β0 genotypes. Blood. 2019;134(1):3543.

54. Lal A et al. Northstar-3: interim results from a phase 3 study evaluating lentiglobin gene therapy in patients with transfusion-dependent β-thalassemia and either a β0 or ivs-110 mutation at both alleles of the HBβ gene. Blood. 2019;134(1):815.

55. bluebird bio. bluebird bio announces temporary suspension on phase 1/2 and phase 3 studies of lentiglobin gene therapy for sickle cell disease (bb1111). 2021. Available at: https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-temporary-suspension-phase-1-and-phase-3#:~:text=(Nasdaq%3A%20BBL%20announced%20today,acute%20myeloid%20leukemia%20(AML). Last accessed: March 2021.

56. Marktel S et al. Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent β-thalassemia. Nat Med. 2019;25(2):234-41.

57. Memorial Sloan Kettering Cancer Center. β-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TN59.3.55 a Lentiviral Vector Encoding the Normal Human β-Globin Gene. NCT01639690. https://clinicaltrials.gov/ct2/show/NCT01639690.

58. Yannaki E et al. Hematopoietic stem cell mobilization for gene therapy of adult patients with severe β-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects. Mol Ther. 2012;20(1):230-8.

59. Gilles AF, Averof M. Functional genomics for all: engineered nucleases, CRISPR and the genome editing revolution. Evodevo. 2015;4.53.

60. European Hematology Association. Corbacioglu S et al. Initial safety and efficacy results with a single dose of autologous crispr-cas9 modified cd34+ hematopoietic stem and progenitor cells in transfusion-dependent β-thalassemia and sickle cell disease. 2020. Available at: https://library.ehaweb.org/eha/2020/eha25th/295100/seq1.corbacioglu.initial.safety.and.efficacy.results.with.a.single.dose.of.html?f=menu%3D%20Abrowsesby%3D%20%2Aasorty%3D%20%2Amedic%3D%3A%20Ace_id%3D%20ID1766%2A%act%3D%2023%20%2AMarker%3D%20%2A-featured%3D%20%2A%3D%20%2Aid%3D%2017675. Last accessed: March 2021.

61. Traxler EA et al. A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition. Nat Med. 2016;22(9):987-90.

62. Zhang KH et al. Off-target effects in CRISPR/Cas9-mediated genome engineering. Mol Ther Nucleic Acids. 2015;4(11):e264.

63. Long J et al. Characterization of gene alterations following editing of the β-globin gene locus in hematopoietic stem/progenitor cells. Mol Ther. 2018;26(2):468-79.

64. Pagani A et al. Hepcidin and anemia: a tight relationship. Front Physiol. 2019;10:1294.

65. Nai A et al. Deletion of Tmprss6 attenuates the phenotype in a mouse model of β-thalassemia. Blood. 2012;119(21):5021-9.

66. Casu C et al. Hepcidin agonists as therapeutic tools. Blood. 2018;131(16):1790-4.

67. Casu C et al. Min hemepcidin peptides as disease modifiers in mice affected by
β-thalassemia and polycythemia vera. Blood. 2016;128(2):265-76.

68. La Jolla Pharmaceutical Company. A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Adult Patients With Transfusion-Dependent Beta Thalassemia. NCT03381833. https://clinicaltrials.gov/ct2/show/NCT03381833.

69. Manolova V et al. Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia. J Clin Invest. 2019;130(1):491-506.

70. Richard F et al. Oral ferroportin inhibitor VIT-2763: first-in-human, phase I study in healthy volunteers. Am J Hematol. 2020;95(1):68-77.

71. Vifor (International) Inc. Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Efficacy of VIT-2763 in β-thalassaemia (VITHAL). NCT04364269. https://clinicaltrials.gov/ct2/show/NCT04364269.

72. Coquerelle S et al. Innovative curative treatment of beta thalassemia: cost-efficacy analysis of gene therapy versus allogenic hematopoietic stem-cell transplantation. Hum Gene Ther. 2019;30(6):753-61.

73. Angelucci E et al. Direct medical care costs associated with β-thalassemia care in Italy. Blood. 2017;130(1):3368.